Philip C. Smith

4.6k citations
121 papers · 3.7k · h-index 35

Impact in

  • Pharmacology top 0.1%
    • Pharmacogenetics and Drug Metabolism
    • Drug-Induced Hepatotoxicity and Protection
    • Inflammatory mediators and NSAID effects
  • Transplantation top 2%

Papers in

Co-authors
Leslie Z. Benet (12 shared papers)John K. Fallon (41 shared papers)Antony F. McDonagh (5 shared papers)Zhiming Wen (7 shared papers)Joseph K. Ritter (8 shared papers)J Hasegawa (2 shared papers)Theunis C. Goosen (3 shared papers)Robert M. Fielding (3 shared papers)
Journals
Drug Metabolism and Disposition (31 papers)Frontiers in Pharmacology (4 papers)Journal of Pharmacology and Experimental Therapeutics (4 papers)Pharmaceutical Research (4 papers)Clinical Pharmacology & Therapeutics (4 papers)
Partner nations
United StatesUnited KingdomJapan

In The Last Decade

Philip C. Smith

118 papers receiving 3.6k citations

Peers

Philip C. Smith
Comparison fields: 5 of 131
  • Pharmacology 1.3k
  • Transplantation 117
  • Oncology 891
  • Pharmacology 544
  • Virology 126
Replace Ute Hofmann with:
Ute Hofmann Germany
A. David Rodrigues United States
Barbara J. Ring United States
Shiew‐Mei Huang United States
Rory P. Remmel United States
Thomayant Prueksaritanont United States
A. David Rodrigues United States
Tommy B. Andersson Sweden
Jiunn H. Lin United States
Robert L. Walsky United States
Philip C. Smith relative to Ute Hofmann Germany Ute Hofmann's profile →
Citations per field
00.5×1.5×2×2.4×
Ute Hofmann · 1×
Citations per year

Countries citing papers authored by Philip C. Smith

Since Specialization
Citations

This map shows the geographic impact of Philip C. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip C. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip C. Smith more than expected).

Fields of papers citing papers by Philip C. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip C. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip C. Smith. The network helps show where Philip C. Smith may publish in the future.

Co-authors

The 25 scholars most cited alongside Philip C. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip C. Smith Line = papers co-authored together Philip C. Smith links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Quantification of Human Uridine-Diphosphate Glucuronosyl Transferase 1A Isoforms in Liver, Intestine, and Kidney Using Nanobore Liquid Chromatography–Tandem Mass Spectrometry
Analytical Chemistry ·David E. Harbourt, John K. Fallon, Shinya Ito, Takashi Baba, Joseph K. Ritter, Gary L. Glish, Philip C. Smith
2011147
2
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans
Genome Research ·Alison H. Harrill, Paul B. Watkins, Stephen Su, Pamela K. Ross, David E. Harbourt, Ioannis M. Stylianou, Gary A. Boorman, Mark W. Russo, Richard S. Sackler, Stephen Harris, Philip C. Smith, Raymond Tennant, Molly A. Bogue, Kenneth Paigen, Christopher M. Harris, Tanupriya Contractor, Timothy Wiltshire, Ivan Rusyn, David W. Threadgill
2009137
3
Irreversible binding of zomepirac to plasma protein in vitro and in vivo.
Journal of Clinical Investigation ·Philip C. Smith, Antony F. McDonagh, Leslie Z. Benet
1986126
4
Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C
The Journal of Clinical Pharmacology ·Roy L. Hawke, Sarah J. Schrieber, Tedi A. Soule, Zhiming Wen, Philip C. Smith, K. Rajender Reddy, Abdus S. Wahed, Steven H. Belle, Nezam H. Afdhal, Victor J. Navarro, Josh Berman, Qiying Liu, Edward Doo, Michael Fried, (unknown)
2009114
5
Targeted Quantitative Proteomics for the Analysis of 14 UGT1As and -2Bs in Human Liver Using NanoUPLC–MS/MS with Selected Reaction Monitoring
Journal of Proteome Research ·John K. Fallon, Hendrik Neubert, Ruth Hyland, Theunis C. Goosen, Philip C. Smith
2013111
6
Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism.
Drug Metabolism and Disposition ·Philip C. Smith, Leslie Z. Benet, Antony F. McDonagh
1990101
7
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats
Antimicrobial Agents and Chemotherapy ·Robert M. Fielding, Philip C. Smith, L. H. Wang, James A. Porter, Lanjun Guo
1991100
8
Quantitative Profiling of Human Renal UDP-glucuronosyltransferases and Glucuronidation Activity: A Comparison of Normal and Tumoral Kidney Tissues
Drug Metabolism and Disposition ·Guillaume Margaillan, Michèle Rouleau, John K. Fallon, Patrick Caron, (unknown), Véronique Turcotte, Philip C. Smith, Melanie S. Joy, Chantal Guillemette
201580
9
Apparent intramolecular acyl migration of zomepirac glucuronide.
Drug Metabolism and Disposition ·J Hasegawa, Philip C. Smith, Leslie Z. Benet
198280
10
Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein
Drug Metabolism and Disposition ·J. William Higgins, Jing Bao, Alice Ke, Jason R. Manro, John K. Fallon, Philip C. Smith, Maciej J. Zamek‐Gliszczynski
201378
11
Toward a Consensus on Applying Quantitative Liquid Chromatography‐Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper
Clinical Pharmacology & Therapeutics ·Bhagwat Prasad, Brahim Achour, Per Artursson, Cornelis E. C. A. Hop, Yurong Lai, Philip C. Smith, Jill Barber, Jacek R. Wiśniewski, Daniel S. Spellman, Yasuo Uchida, Michael Zientek, Jashvant D. Unadkat, Amin Rostami‐Hodjegan
201977
12
Disposition and irreversible plasma protein binding of tolmetin in humans
Clinical Pharmacology & Therapeutics ·Martha L. Hyneck, Philip C. Smith, Alain Munafo, Antony F. McDonagh, Leslie Z. Benet
198870
13
UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme Kinetics
Drug Metabolism and Disposition ·Zhiming Wen, Melanie N. Tallman, Shazia Ali, Philip C. Smith
200668
14
Stability of acyl glucuronides in blood, plasma, and urine: studies with zomepirac.
Drug Metabolism and Disposition ·Philip C. Smith, J Hasegawa, Pim N.J. Langendijk, Leslie Z. Benet
198568
15
The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity
Drug Metabolism and Disposition ·Sarah J. Schrieber, Zhiming Wen, Manoli Vourvahis, Philip C. Smith, Michael Fried, Angela D. M. Kashuba, Roy L. Hawke
200868
16
Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac
Clinical Pharmacology & Therapeutics ·Philip C. Smith, Pim N.J. Langendijk, John A. Bosso, Leslie Z. Benet
198562
17
The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil
The Journal of Clinical Pharmacology ·Odin Naderer, Robert E. Dupuis, Erin L. Heinzen, Kamonthip Wiwattanawongsa, Mark W. Johnson, Philip C. Smith
200561
18
Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction Monitoring
Drug Metabolism and Disposition ·John K. Fallon, Hendrik Neubert, Theunis C. Goosen, Philip C. Smith
201360
19
Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers
Antimicrobial Agents and Chemotherapy ·David E. Martin, Robert A. Blum, John H. Wilton, Judy Doto, Hal Galbraith, Gina L. Burgess, Philip C. Smith, Charles H. Ballow
200757
20
AN INVESTIGATION OF HUMAN AND RAT LIVER MICROSOMAL MYCOPHENOLIC ACID GLUCURONIDATION: EVIDENCE FOR A PRINCIPAL ROLE OF UGT1A ENZYMES AND SPECIES DIFFERENCES IN UGT1A SPECIFICITY
Drug Metabolism and Disposition ·Kristini K. Miles, Stęphan T. Stern, Philip C. Smith, Fay K. Kessler, Shazia Ali, Joseph K. Ritter
200552

About Philip C. Smith

Philip C. Smith is a scholar working on Molecular Biology, Oncology, Pharmacology, Pharmacology and Infectious Diseases, having authored 121 papers that have together received 3.7k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (30 papers), Drug Transport and Resistance Mechanisms (29 papers), Inflammatory mediators and NSAID effects (14 papers), Drug-Induced Hepatotoxicity and Protection (10 papers), HIV/AIDS drug development and treatment (9 papers), Analytical Methods in Pharmaceuticals (8 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Mass Spectrometry Techniques and Applications (7 papers). The work is most often cited by research in Pharmacology (1.3k citations), Transplantation (117 citations), Oncology (891 citations), Pharmacology (544 citations) and Virology (126 citations). Philip C. Smith has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Leslie Z. Benet, John K. Fallon, Antony F. McDonagh, Zhiming Wen, Joseph K. Ritter, J Hasegawa, Theunis C. Goosen, Robert M. Fielding, Hendrik Neubert and Melanie N. Tallman. Their work appears in journals such as Drug Metabolism and Disposition, Frontiers in Pharmacology, Journal of Pharmacology and Experimental Therapeutics, Pharmaceutical Research and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ute HofmannBreakdown of academic impact, for papers by A. David RodriguesBreakdown of academic impact, for papers by Barbara J. RingBreakdown of academic impact, for papers by Shiew‐Mei HuangBreakdown of academic impact, for papers by Rory P. RemmelBreakdown of academic impact, for papers by Thomayant PrueksaritanontBreakdown of academic impact, for papers by A. David RodriguesBreakdown of academic impact, for papers by Tommy B. AnderssonBreakdown of academic impact, for papers by Jiunn H. LinBreakdown of academic impact, for papers by Robert L. Walsky